Venmax Drugs and Pharmaceuticals has reported a financial turnaround, swinging to a profit of Rs 0.25 crore in FY26 from a loss in the prior year. Revenue jumped significantly to Rs 8.02 crore. The company is currently awaiting NCLT approval for the merger with Hatri Pharma and has announced key leadership changes.
Venmax Drugs and Pharmaceuticals Reports Financial Turnaround
Profit After Tax: Rs 0.25 crore (up from loss of Rs 0.01 crore in FY25).
Revenue from operations: Rs 8.02 crore (up from Rs 0.81 crore in FY25).
Reader Takeaway: Revenue surge drives bottom-line recovery; NCLT approval for Hatri Pharma merger remains the critical strategic milestone.
What just happened
Venmax Drugs and Pharmaceuticals Ltd has returned to profitability for the fiscal year ended March 31, 2026. The firm recorded a profit after tax of Rs 0.25 crore, reversing the loss of Rs 0.01 crore seen in the previous fiscal year. Operational revenue grew substantially to Rs 8.02 crore compared to Rs 0.81 crore in the year prior.
Corporate Developments
The company is currently executing a scheme of amalgamation to merge Hatri Pharma Private Limited into its operations. The board approved this proposal on November 12, 2025, and received an NOC from the BSE in May 2026. The matter is currently under review by the NCLT, Hyderabad Bench, following a First Motion Application filed in August 2026.
Management Changes
Leadership restructuring has been finalized with Venkata Rao Sadhanala redesignated as Managing Director for a five-year term ending in 2031. Additionally, the company appointed Padmaja Kalyani Sadhanala and Revoor Ramachandra as Additional Directors effective March 30, 2026.
What to track next
Investors should look for the upcoming 37th Annual General Meeting scheduled for September 26, 2026. Ongoing monitoring of the NCLT proceedings regarding the Hatri Pharma amalgamation is advised as it represents a core strategic pivot for the entity.